Promiscuous MYC locus rearrangements hijack enhancers but mostly super-enhancers to dysregulate MYC expression in multiple myeloma

Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells

(2013) B. A. Walker et al.   BLOOD

Diverse Mechanisms of Somatic Structural Variations in Human Cancer Genomes

(2013) Lixing Yang et al.   CELL

Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

(2013) Jakob Lovén et al.   CELL

Super-Enhancers in the Control of Cell Identity and Disease

(2013) Denes Hnisz et al.   CELL

Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants

(2013) S. C. J. Parker et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

MYC addiction: a potential therapeutic target in MM

(2012) W. M. Kuehl et al.   BLOOD

Addiction to c-MYC in multiple myeloma

(2012) T. Holien et al.   BLOOD

Frequent PVT1 Rearrangement and Novel Chimeric Genes PVT1-NBEA and PVT1-WWOX Occur in Multiple Myeloma with 8q24 Abnormality

(2012) H. Nagoshi et al.   CANCER RESEARCH

Molecular pathogenesis of multiple myeloma and its premalignant precursor

(2012) W. Michael Kuehl et al.   JOURNAL OF CLINICAL INVESTIGATION

Germline Deletion of Igh 3' Regulatory Region Elements hs 5, 6, 7 (hs5-7) Affects B Cell-Specific Regulation, Rearrangement, and Insulation of the Igh Locus

(2012) S. A. Volpi et al.   JOURNAL OF IMMUNOLOGY

The role of CTCF binding sites in the 3′ immunoglobulin heavy chain regulatory region

(2012) Barbara K. Birshtein   Frontiers in Genetics

BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc

(2011) Jake E. Delmore et al.   CELL

Mapping of Chromosome 1p Deletions in Myeloma Identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as Being Genes in Regions Associated with Adverse Survival

(2011) K. D. Boyd et al.   CLINICAL CANCER RESEARCH

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

Mapping and analysis of chromatin state dynamics in nine human cell types

(2011) Jason Ernst et al.   NATURE

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

(2010) D. Hose et al.   HAEMATOLOGICA

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

(2010) R A Kyle et al.   LEUKEMIA

Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells

(2009) Ernesto Pérez-Persona et al.   BRITISH JOURNAL OF HAEMATOLOGY

Frequent upregulation ofMYCin plasma cell leukemia

(2009) Laura Chiecchio et al.   GENES CHROMOSOMES & CANCER

Loss of 1p and rearrangement of MYC are associated with progression of smouldering myeloma to myeloma: sequential analysis of a single case

(2009) L. Chiecchio et al.   HAEMATOLOGICA

AID-Dependent Activation of a MYC Transgene Induces Multiple Myeloma in a Conditional Mouse Model of Post-Germinal Center Malignancies

(2008) Marta Chesi et al.   CANCER CELL

Secondary genomic rearrangements involving immunoglobulin or MYC loci show similar prevalences in hyperdiploid and nonhyperdiploid myeloma tumors

(2008) Ana Gabrea et al.   GENES CHROMOSOMES & CANCER

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma

(2007) A. Dispenzieri et al.   BLOOD